Jubilant Ingrevia Limited announced successful outcome of the USFDA inspection with the receipt of Establishment Inspection report (EIR) with Zero 483 inspectional observations for the inspection performed in the month of April, 2024 at our Manufacturing facility, Unit -1 located at Bharuch, Gujarat, India.

Speaking on the development, Deepak Jain, CEO & Managing Director, Jubilant Ingrevia Limited said, "We are pleased to share that our manufacturing site, Unit-1, intended for the manufacturing of Nutraceuticals & Dietary- Active ingredients for Human consumption in a GMP compliant facility located at Bharuch, Gujarat India has successfully undergone its maiden USFDA inspection with the outcome of zero 483 inspectional observations. This accomplishment reiterates our company's unwavering commitment to maintain highest quality and compliance standards. It is also testament to our entire team's dedication and capability to achieve a common objective that reinforces our leadership position in delivering safe, effective and high-quality compliant products to our customers.

"This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the Company's strategic capex initiative, shall position Jubilant Ingrevia further to capitalize and mark Company's foray into regulated market to cater the growing business requirements in the Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications - Active Ingredients, Drug Intermediates, CDMO products intended for industry application and human consumption.